Meeting NewsVideo

VIDEO: Anabolic agents should be prescribed early for high-risk osteoporosis

PHILADELPHIA — In this video exclusive, Neil C. Binkley, MD, professor in the divisions of geriatrics and endocrinology, associate director of the Institute on Aging and co-director or the Osteoporosis Clinical Center and Research Program at the University of Wisconsin-Madison, discusses the most recent medications available for treatment of osteoporosis.

“We as a field have been doing a poor job of treating people after they have sustained fractures,” Binkley said. Two anabolic agents – teriparatide (Forteo, Eli Lilly) and abaloparatide (Tymlos, Radius Health) — are currently available to build bone, and physicians should be using these much more widely in people at high risk for fracture, Binkley said. These agents work best when prescribed before anti-resorptive therapies as studies have shown that earlier anti-resporptive treatment blunts their effects.

PHILADELPHIA — In this video exclusive, Neil C. Binkley, MD, professor in the divisions of geriatrics and endocrinology, associate director of the Institute on Aging and co-director or the Osteoporosis Clinical Center and Research Program at the University of Wisconsin-Madison, discusses the most recent medications available for treatment of osteoporosis.

“We as a field have been doing a poor job of treating people after they have sustained fractures,” Binkley said. Two anabolic agents – teriparatide (Forteo, Eli Lilly) and abaloparatide (Tymlos, Radius Health) — are currently available to build bone, and physicians should be using these much more widely in people at high risk for fracture, Binkley said. These agents work best when prescribed before anti-resorptive therapies as studies have shown that earlier anti-resporptive treatment blunts their effects.

    See more from North American Menopause Society Annual Meeting